Mölnlycke appoints Barry McBride as interim CEO
As of 1 August, Barry McBride, EVP Gloves, Antiseptics and Global R&D, will take on the role as interim CEO for Mönlycke until the new CEO, Zlatko Rihter joins the company.
"Zlatko Rihter may not be able to take on his position as President and CEO of Mölnlycke until end of November. The Board has therefore decided to ask Barry McBride to act as interim President and CEO as of 1 August, and until Zlatko Rihter is able to start," says Gunnar Brock, chairman of the Mölnlycke Board.
Barry McBride joined Mölnlycke in 2014 as Executive Vice President R&D. Since then, he has added the Gloves and Antiseptics franchises as well as the Medical and Economics function to his responsibilities.
“Barry has been with the company for several years and has a broad knowledge of the business. I am confident he is well positioned to lead the company during the coming months, while also maintaining his current responsibilities,” says Gunnar.
The current CEO, Richard Twomey, will leave his position as of 1 August 2020, and act as an advisor to the Mölnlycke Board.
For more information, please contact:
Global Director Corporate Communications
+46 317 223 423 or email@example.com
Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply products and solutions for use in wound treatment, pressure ulcer and infection prevention and surgery.
Mölnlycke employs around 7,800 people. The company headquarters are in Gothenburg, Sweden and we operate in more than 100 countries worldwide. Since 2007, the company is part of Investor AB, an engaged owner of high-quality, global companies which was founded by the Wallenberg family in 1916. For more information, please visit www.molnlycke.com